Fig. 4: The high therapeutic effect of Mito-G on HFD + STZ mice model. | Nature Communications

Fig. 4: The high therapeutic effect of Mito-G on HFD + STZ mice model.

From: UCP2 inhibition eliminates pancreatic β cell autoinflammation in T2DM with islet-mitochondrial sequential targeting nanomedicines

Fig. 4: The high therapeutic effect of Mito-G on HFD + STZ mice model.The alternative text for this image may have been generated using AI.

A The FBGL of mice during the drug treatment (n = 6). B IPGTT was measured after 3 weeks of drug administration (n = 6). C ITT was measured after 4 weeks of drug administration (n = 6). D The level of serum HbA1c from each group (n = 6). E Representative H&E images of pancreatic sections from each group (n = 3). Scale bar: 100 μm. F, G Representative immunofluorescent staining (F) and quantitative analysis (G) of insulin (green), glucagon (red), and DAPI (blue) of the pancreas sections from each group (n = 3). Scale bar: 50 μm. H TEM of pancreatic islets from each group. Red and blue arrowheads point to vesicles containing mature and immature granules, respectively. Scale bar: 1 μm. I The serum insulin level from each group (n = 6). J–M mRNA levels of Insulin, Neurod1, Mafa, and Pdx1 in pancreatic tissues from each group (n = 6). Data are presented as mean values ± SD from different biological replicates. Statistical significance was calculated by one-way ANOVA with Tukey’s post-test. Source data are provided as a Source Data file.

Back to article page